Polymorphisms in the activin a receptor type 2A gene affect the onset time and severity of preeclampsia in the Turkish population

Journal of Perinatal Medicine

Volumn 41, Issue 4, 2013, Pages 389-399

  Zeybek, Burak ^a   Ak Celik, Handan ^a   Aydin, Hikmet Hakan ^a   Askar, Niyazi ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Activin a receptor type 2A gene; Preeclampsia; Single nucleotide polymorphisms

Indexed keywords

ACTIVIN A; ACTIVIN A RECEPTOR 2A; GENOMIC DNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY (REPUBLIC); VENOUS BLOOD;

ACTIVIN RECEPTORS, TYPE II; ADULT; BIRTH WEIGHT; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRE-ECLAMPSIA; PREGNANCY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TURKEY; YOUNG ADULT;

EID: 84881586564     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2012-0187     Document Type: Article

References (33)

1. Arngrimsson R, Bjornsson S, Geirsson RT, Bjornsson H, Walker JJ, Snaedal G. Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol. 1990;97:762 - 9.
2. Arngrimsson R, Sigurard ttir S, Frigge ML, Bjarnad ttir RI, Jonsson T, Stefansson H, et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet. 1999;8:1799 - 805.
3. Caniggia I, Lye SJ, Cross JC. Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology. 1997;138:3976 - 86.
4. Cocolakis E, Lemay S, Ali S, Lebrun JJ. The p38MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem. 2001;276:18430 - 6.
5. Davison JM, Homuth V, Jeyabalan A, Conrad KP, Karumanchi SA, Quaggin S, et al. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol. 2004;15:2440 - 8.
6. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992;99:547 - 53.
7. Fitzpatrick E, Goring HH, Liu H, Borg A, Forrest S, Cooper DW, et al. Fine mapping and SNP analysis of positional candidates at the pre-eclampsia susceptibility locus (PREG1) on chromosome 2. Hum Biol. 2004;76:849 - 62.
8. Fitzpatrick E, Johnson MP, Dyer TD, Forrest S, Elliott K, Blangero J, et al. Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Mol Hum Reprod. 2009;15: 195 - 204.
9. Harrison GA, Humphrey KE, Jones N, Badenhop R, Guo G, Elakis G, et al. A genome-wide linkage study of preeclampsia/eclampsia reveals evidence for a candidate region on 4q. Am J Hum Genet. 1997;60:1158 - 67.
10. Hedger MP, Winnall WR, Phillips DJ, de Kretser DM. The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm. 2011;85:255 - 97.
11. Laivuori H, Lahermo P, Ollikainen V, Widen E, Haiva-Mallinen L, Sundstrom H, et al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet. 2003;72:168 - 77.
12. Lindheimer MD, Taler SJ, Cunningham FG. ASH position article: hypertension in pregnancy. J Am Soc Hypertens. 2008;2:484 - 9.
13. Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahon LP, et al., for the Society of Obstetric Medicine of Australia and New Zealand. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol. 2009;49:242 - 6.
14. Magee LA, Helewa ME, Moutquin JM, von Dadelszen P, Hypertension Guideline Committee, Society of Obstetricians and Gynaecologists of Canada. SOGC guidelines; diagnosis, evaluation and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol. Can. 2008;30:1 - 48.
15. Mathews LS, Vale WW. Expression cloning of an activin receptor, a predicted transmembrane serin kinase. Cell. 1991;65:973 - 82.
16. Molvarec A, Jermendy A, Nagy B, Kovacs M, V arkonyi T, Hupuczi P, et al. Association between tumor necrosis factor (TNF)-alpha G-308A gene polymorphism and preeclampsia complicated by severe fetal growth restriction. Clin Chim Acta. 2008;392:52 - 7.
17. Molvarec A, Ver A, Fekete A, Rosta K, Derzbach L, Derzsy Z, et al. Association between estrogen receptor alpha (ESR1) gene polymorphisms and severe preeclampsia. Hypertens Res. 2007;30:205 - 11.
18. Moses EK, Fitzpatrick E, Freed KA, Dyer TD, Forrest S, Elliott K, et al. Objective prioritization of positional candidate genes at a quantitative trait locus for pre-eclampsia on 2q22. Mol Hum Reprod. 2006;12:505 - 12.
19. Moses EK, Lade JA, Guo G, Wilton AN, Grehan M, Freed K, et al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet. 2000;67:1581 - 5.
20. Ong S, Lash G, Baker PN. Angiogenesis and placental growth in normal and compromised pregnancies. Best Pract Res Clin Obstet Gynaecol. 2000;14:969 - 80.
21. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. Firsttrimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53:812 - 8.
22. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50:137 - 42.
23. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001;357:53- 6.
24. Roten LT, Johnson MP, Forsmo S, Fitzpatrick E, Dyer TD, Brennecke SP, et al. Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). Eur J Hum Genet. 2009;17:250 - 7.
25. Salonen RH, Lichtenstein P, Lipworth L, Cnattingius S. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet. 2000;91: 256 - 60.
26. Sutherland A, Cooper DW, Howie PW, Liston WA, MacGillivray I. The incidence of severe pre-eclampsia amongst mothers and mothers-in-law of pre-eclamptics and controls. Br J Obstet Gynaecol. 1981;88:785 - 91.
27. Thornton JG, MacDonald AM. Twin mothers, pregnancy hypertension and pre-eclampsia. Br J Obstet Gynaecol. 1999;106:570 - 5.
28. Thornton JG, Onwude JL. Pre-eclampsia: discordance among identical twins. Br Med J. 1991;303:1241 - 2.
29. Tuffnell DJ, Shennan AH, Waugh JJS, Walker JJ. The management of severe pre-eclampsia/eclampsia, guideline number 10(A). London: Royal College of Obstetricians and Gynaecologists; 2006.
30. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia: pathophysiology, diagnosis and management. Vasc Health Risk Manag. 2011;7:467 - 74.
31. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22: 143 - 8.
32. Zhang Z, Zhao Y, Batres Y, Lin MF, Ying SY. Regulation of growth and prostatic marker expression by activin A in an androgensensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun. 1997;234:362 - 5.
33. Zusterzeel PL, Peters WH, Visser W, Hermsen KJ, Roelofs HM, Steegers EA. A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia. J Med Genet. 2001;38:234 - 7.